Sumano LH, Gutiérrez OL

Idioma: Español/Inglés
Referencias bibliográficas: 38
Paginas: 137-145
Archivo PDF: 62.15 Kb.

RESUMEN

More than two decades ago, enrofloxacin, a fluoroquinolone, was first used in Mexico and Latin America. This agent was and still is, regarded as the most potent antibacterial agent available in veterinary medicine. At first, it was dosed at a rate of 5 mg/kg/day and it was retailed in a 5% solution. Today the dose has been increased to 10 mg/kg/day, and it is commercially available in 10% solutions. This trend indicates a tendency towards increasing bacterial resistance, which coincides with vast amount, and unpublished communications of lack of clinical trials and reports of demonstrated bacterial resistance. Additionally, the availability in the market pharmaceutical analogs of uncontrolled quality, plus the careless use of the drug under field conditions may be more relevant to the perceived clinical failure than a hypothetical bacterial resistance surge. In this paper, an overview on the use and abuse of enrofloxacin is presented. Considering that understanding enrofloxacin is the most potent antibacterial so far found for veterinary medicine, authors regarded as important present the current status of the use of enrofloxacin in the poultry industry. The main pharmacological features of this drug are presented within the context of its use in Mexico and many Latin American settings, hoping with this, to improve the way in which enrofloxacin is given in daily clinical practice.

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1. Prescott JF. Antimicrobial susceptibility testing and antimicrobial drug dosage. J Am Vet Med Assoc 1980;10: 1085-1090.

2. 2. Blanco JE, Blanco M, Mora A, Blanco J. Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherechia coli strains isolated from septicemic and healthy chickens in Spain. J Clin Microbiol 1997;5:2184-2185.

3. 3. Baggot JD. Distribution of antimicrobial agents in normal and diseased animals. J Am Vet Med Assoc 1980;10:1085-1090.

4. 4. Prescott JF, Baggot JD. Antimicrobial therapy in veterinary medicine. 2nd ed. Ames (Io): Iowa State University Press, 1993.

5. 5. Sumano LH. Quinolonas y fluoroquinolonas en medicina veterinaria. Vet Méx 1993;2: 23-34.

6. 6. Goater E. Utilisation des antifectieux dans l’espèce poule. L’Aviculteur 1988;486:1-12.

7. 7. Puyt JD. Antibiotic therapy in poultry production. Bulletin-dans- G T V 1995;5:17-109.

8. 8. Russel ID. Proper water medication with good water systems. Poultry Digest 1992;54:40-48.

9. 9. Wages DP. Proper medication procedures. Poultry Digest 1997;56:18-19.

10. Rodríguez-García R. Evaluación de la mezcla enrofloxacina trimetroprim in vitro (tesis licenciatura). México (DF): México: Facultad de Medicina Veterinaria y Zootecnia. UNAM, 1997.

11. Randandt JM, Randall MC, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infec Dis 1992;14:272-284.

12. Dorrestein DJ, Van Miert ASJPAM. Pharmacotherapeutic aspects of medication of birds. J Vet Pharmacol Ther 1988;11:33-44.

13. Prukner Rodovcic E; Rukavina V; Mazija H; Prpic B. Effect of quinolones (enrofloxacin) on the productivity and immune status of brailers. (Ucinak kinolona na prozvodna svojsta I na zdravlje imunog sustavo-tovih pilica). Praxis Veterinaria Zagreb. 1993;41:143-153.

14. Medders WM, Wooley RE, Gibbs PS, Shotts EB, Broen J. Mutation rate of avian intestinal coliform bacteria when pressured with fluoroquinolones. Avian Dis 1998; 1:146-53.

15. Abd el Aziz MI, Agag AE. Influence of some antibiotics used as growth promotors on immune response of chickens. Assiut Vet Med J 1996;35:64-75.

16. Koenraad PMFJ, Jacobs-Reitsma WF, Laan Van Der T, Beumer RR, Rombouts FM. Antibiotic susceptibility of Campylobacter isolates from sewage and poultry abattoir drain water. Epidemiol Infec 1996;115:475-483.

17. Nikolovski J, Nikolovski-Stefanovic Z, Damnjanovic N, Kaluderovic V. Selection and application of antibiotics in treatment of bacterial diseases in poultry. Zivinarstvo 1997;32:207-211.

18. Piddock LJV, Wray C, McClaren I, Wise R. Quinolone resistance in Salmonella sp.: veterinary pointers. Lancet 1995;336:125.

19. Shlosberg A, Ershov E, Bellaiche M, Hanji V, Weisman Y, Soback S. The effects of enrofloxacin on hepatic microsomal mixed function oxidase in broiler chickens. J Vet Pharmacol Ther 1995;18:311-313.

20. Sumano LH, Gracia MI, Romero V, Ruiz-Ramirez L. The use of ciprofloxacin in proprietary products of enrofloxacin. Vet Hum Toxicol 1994;5:476-477.

21. Sumano LH, Ocampo CL. Compositional analysis surveillance of eleven trade brands of enrofloxacin including Baytril, for veterinary use. J Vet Med 1995:7:152-178.

22. Sumano LH, Ocampo CL, Farmacología veterinaria. 2ª ed. México. (DF): McGraw-Hill-Interamericana, 1997.

23. Aramayona JJ, Mora J, Fraile LJ. Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drug in lactating rabbits and neonatal of offspring. Am J Vet Res 1996;4:547-53.

24. Shenl L, Pernet AG. Mechanism of inhibition of DNA gyrase by quinolone antibacterials; specificity and cooperativity of drug binding the DNA. Biochemistry 1989;28: 3879-3885.

25. Abd-el-Aziz MI, Azis MA, Soliman FA, Afify NA. Pharmacokinetic evaluation of enrofloxacin in chickens. British Poultry. Vet Med Rev 1987;2:130-136.

26. Andon A, Martinez MR, Diaz MJ, Bringas P, Martinez MA, Fernandez-Cruz ML, Fernandez MC, Fernandez R. Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 1995;56:501-506.

27. Anne E, Asuquo J, Piddock V. Accumulation and killin kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 1993;31;865-880.

28. Brown SA. Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996;19:1-14.

29. Intorre L, Mengozzi G. Bertini S, Bagliacca M, Luchetti E, Soldani G. The plasma kinetics and tissue distribution of enrofloxacin and metabolite ciprofloxacin in the Muscovy duck. Vet Res Commun 1997;21:127-136.

30. Hubert E, Mouton PR, Van Der Reyden T, Ruijus GJ, Biever M. Fluoroquinolone resistance in Campylobacter sp isolated for human stools and poultry products. Lancet 1997;335:787.

31. Koenrad PMJF, Jacobs-Reitsman WF. LaanT, Beumer RR, Pombouts FM. Antibiotics susceptibility of Campylobacter isolated from sewage and poultry abattoir drain water. Epidemiology 1995;115:475-483.

32. Kho HB, Kang MI, Kim GN. Antimicrobial drugs susceptibility of Mycoplasma gallisepticum isolated from chronic respiratory diseases outbreaks. Korean J Vet Public Health 1993;17:63-68.

33. Garcia-Ovando H, Luders C, Gorla N, Errecalde C, Prieto G. Intravenous pharmacokinetics of enrofloxacin and ciprofloxacin in broiler chickens. Proceedings of the 7th European Association for Veterinary Pharmacology and Toxicology International Congress; 1997 July 6-10. Madrid, Spain. Jvet Pharmacol Ther. 1997;20(suppl):203-204.

34. Kietzmann M, Knoll U, Glunder G. Pharmacokinetics of enrofloxacin and danofloxacin in broiler chickens. J Vet Pharmacol Ther 1997;20(suppl):202.

35. Andon A, Martinez-Larrañaga MR, Diaz MJ, Velez C, Bringas P, Pharmacokinetic and residue studies of quinolone compounds and olaquindox in poultry. Ann Rech Vet 1990:21:137-144.

36. Erdeger J, Diker KD. Multiple antibiotic resistance in poultry isolates of Campylobacter. J Antimicrob Chemother 1991;27:199-208.

37. Aarestrup FM, Nielsen EM, Madsen M, Engberg J. Antimicrobial susceptibility patterns of thermophilic Campylobacter spp. for humans, pigs, cattle and broilers in Denmark. J Antimicrob Agents Chemother 1997;41: 2244-2250.

38. Jacobs-Reitsman WF, Koenraad PMFJ, Bolder NM, Mulder RWAW. In vitro susceptibility of Campylobacter and Salmonella isolates from broilers to quinolones, ampicillin, tetracycline and erytromicine. Vet Q 1994;4: 199-208.